Specialty pharmacies and online companies that have been selling off-brand copies of two blockbuster drugs for obesity and ...

Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep ...

Eli Lilly And Co. LLY, a top pick for the firm, is projected to see continued growth in its diabetes and obesity treatments, ...

Lilly investors got the jitters, saw better opportunities elsewhere, or decided to hold onto their chips. In the third ...

Our analyst team just revealed what they believe are the 10 best stocks to buy right now. See the 10 stocks » They are Apple, ...

Independence Blue Cross joins other insurance companies in restricting coverage of Wegovy and Ozempic to Type 2 diabetes and ...

Investing in dividend stocks is a great strategy for many reasons, including the potential they offer you to significantly ...

Since pharmaceutical giant Eli Lilly (NYSE: LLY) reported earnings for the third quarter on Oct. 30, shares have been ...

Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and ...

The Food and Drug Administration today approved Eli Lilly’s weight-loss treatment, Zepbound, for obstructive sleep apnea, ...

The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and ...

The FDA has approved Eli Lillys Zepbound as the first weight-loss drug to treat obstructive sleep apnea, reshaping care for ...